Viridian Therapeutics, Inc.\DE (VRDN) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$70.8M

Net Income/Loss (FY2025)

-$342.6M

Total Assets (FY2025)

$899.4M

Total Equity (FY2025)

$722.2M

Cash Flows from Operating Activities (FY2025)

-$276.4M

Source: Viridian Therapeutics, Inc.\DE 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.